MRK - Merck & Co., Inc.
71.60 +0.38 (0.53%)
After hours: 6:46PM EDT
| Previous close | 69.46 |
| Open | 69.85 |
| Bid | 70.30 x 800 |
| Ask | 71.90 x 2900 |
| Day's range | 69.75 - 71.31 |
| 52-week range | 52.83 - 72.89 |
| Volume | 10,229,047 |
| Avg. volume | 8,109,273 |
| Market cap | 189.412B |
| Beta (3Y Monthly) | 0.98 |
| PE ratio (TTM) | 146.85 |
| EPS (TTM) | 0.49 |
| Earnings date | 25 Oct 2018 |
| Forward dividend & yield | 1.92 (2.75%) |
| Ex-dividend date | 2018-09-14 |
| 1y target est | 75.99 |
- Yahoo Finance•2 hours ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
- Zacks•4 hours ago
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
Market Realist•5 hours agoWhat Nektar Therapeutics’ Valuation Trend Indicates
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Market Realist•5 hours agoAnalyzing Nektar Therapeutics’ Operational Performance
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
CNBC•12 hours agoStocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more
These are the stocks posting the largest moves before the bell.
- Business Wire•13 hours ago
U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer
Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA
- The Wall Street Journal•15 hours ago
[$$] European Corporate News Roundup
A $900 million disposal by Spain’s Iberdrola and a revenue warning from British American Tobacco are the corporate highlights in Europe on Tuesday.
Market Realist•yesterdayMerck’s Operating Expenditure and Recent Developments
Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.
Market Realist•yesterdayMerck Is Expected to Record Steady Revenue Growth in Q3
Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.
- Market Realist•yesterday
Novartis in Q3 2018: Analysts Expect Revenue Growth
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
- Zacks•yesterday
This is Why Merck (MRK) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Market Realist•4 days agoWhat Vertex Pharmaceuticals’ Valuation Trend Indicates
In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.
- Zacks•4 days ago
3 Large-Cap Pharma Stocks Performing Better Than Industry
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
- Zacks•4 days ago
Is This the Right Time to Enter Dow? 4 Great Picks
A glimpse at the 30-stock blue-chip index will reveal that the recent meltdown is likely to be transitory and can provide a good entry point for investors.
